Mechanism of action<unk>  binds to IL-5 and prevents it from binding to its receptor, more specifically the interleukin 5 receptor alpha subunit, on the surface of eosinophil white blood cells. While eosinophils play a role in inflammation associated with asthma, the exact mechanism of<unk>  is unknown. Pharmacokinetics After subcutaneous injection,<unk>  has an estimated bioavailability of 80% and reaches highest blood plasma concentrations after four to eight days. Like other antibodies, it is degraded by proteolytic enzymes. Its biological half-life is 20 days on average, ranging from 16 to 22 days in different individuals.
Mepolizumab
Vedolizumab
Certolizumab pegol
Nemolizumab
Natalizumab
Belatacept
Brolucizumab
Reslizumab